(Alliance News) - Hutchmed (China) Ltd on Thursday said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration.
If accepted, the Hong Kong-based developer of treatments for cancer and immunological diseases said that the new label indication for savolitinib will be expanded to include treatment-naive patients in China.
A treatment-naive patient is someone who has not received any treatment.
Savolitinib is a treatment for adult patients with locally advanced or metastatic non-small cell lung cancer. It had previously been granted conditional approval in China. "
More than a third of the world's lung cancer patients are in China," Hutchmed said.
Shares in Hutchmed were flat at USD16.69 each in London on Thursday morning.
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Hutchmed (HCM)